Allox Funding Round

10/29/2026

Venture Equity

$10,500,000

Seed

The company intends to use the funds to scale and expand its platform capabilities, develop proprietary AI models, strengthen its internal drug discovery team, advance multiple drug discovery programs, and enable strategic research collaborations.

Private & Independent

Biopharmaceutical

C/ Baldiri Reixac, 4-12 i 15 (Torre R)
Barcelona, 08028
Spain

Undisclosed

ALLOX is a spin-off of the Centre for Genomic Regulation (CRG) and draws on the expertise and technology developed in the lab of Ben Lehner. The company was born out of the realisation that combining systematic mutagenesis, high-throughput phenotyping and biophysical modelling has the potential to revolutionise drug development but also transform biotechnology in general. We are currently incubating in the beautiful beachfront setting of the Barcelona Biomedical Research Park (PRBB), and our immediate goal is to identify allosteric switches in all proteins and then leverage this unprecedented resource to rapidly develop novel medicines to treat human diseases. Our long-term vision is to become a leader in programmable biology, building the next generation of tools to predict, design and engineer new protein functions.